Agennix AG / Agennix AG Announces Presentation of New Data from Talactoferrin Randomized, Double-Blind, Placebo-Controlled Phase II Trial in Severe Sepsis at American Thoracic Society International Conference processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. 


  Agennix AG Announces Presentation of New Data from Talactoferrin Randomized,
               Double-Blind, Placebo-Controlled Phase II Trial in
      Severe Sepsis at American Thoracic Society International Conference
  * Results show talactoferrin reduces 28-day all-cause mortality across wide
    range of baseline prognostic factors, including APACHE II score
  * Results show no significant differences in adverse events for talactoferrin
    compared to placebo


Martinsried/Munich  (Germany),  Princeton,  NJ  and  Houston, TX, May 17, 2010 -
Agennix  AG (Frankfurt Stock Exchange: AGX)  today announced the presentation of
promising  new activity and safety data from a Phase II trial with talactoferrin
in  severe  sepsis  at  the  International  Conference  of the American Thoracic
Society  in New Orleans, Louisiana.   The double-blind, placebo-controlled trial
evaluated  talactoferrin versus placebo in 190 adult patients with severe sepsis
enrolled  at  25 leading  centers  across  the  U.S.  Patients in both arms also
received  standard of care treatment for severe sepsis in an intensive care unit
(ICU) setting.  The data presented today show that talactoferrin reduced 28-day
all-cause  mortality in the  overall population by  12% compared to placebo (45%
relative  reduction) and  appeared to  show an  effect across  a broad  range of
baseline  characteristics, including APACHE II score, cardiovascular dysfunction
and  the  number  and  type  of  organ  dysfunctions, all of which are important
prognostic  factors for  severe sepsis.   The results  showed that talactoferrin
also  reduced all-cause mortality compared to placebo  over the longer term - at
three months and at six months.

Kalpalatha  Guntupalli, M.D., Professor  and Chief, Pulmonary  Critical Care and
Sleep  Medicine, Baylor  College of  Medicine and  principal investigator of the
talactoferrin  Phase  II  trial,  said:  "There  are currently limited treatment
options for patients with severe sepsis, a condition that is very challenging to
treat  and  for  which  the  mortality  rate is approximately 30-40%. This study
demonstrates  that talactoferrin  has the  potential to  have a  major impact on
reducing  mortality in  patients with  severe sepsis  and that  this improvement
appears  to be consistent regardless of APACHE II baseline score.  Talactoferrin
was also shown to be well tolerated in this very sick patient population."

Rajesh  Malik, M.D., Chief  Medical Officer of  Agennix AG, said:   "We are very
excited   about   the  data  presented  today  from  our  Phase  II  trial  with
talactoferrin in severe sepsis.  Once we have met with regulatory authorities to
discuss  these data and our plans, we  look forward to advancing the development
of talactoferrin for this indication."

The  Phase II  trial achieved  its primary  endpoint of  a reduction  in 28-day
all-cause  mortality from 26.6% in the placebo arm to 14.6% in the talactoferrin
arm  (two-tailed unadjusted  p-value =  0.04, odds ratio  by logistic regression
analysis = 0.47), as previously disclosed.  Patients were stratified by clinical
site and by the presence or absence of cardiovascular dysfunction due to sepsis.
 When  the  trial  results  were  adjusted  for  cardiovascular dysfunction, the
two-tailed p-value was 0.06, and the odds ratio was 0.49.

Sixty-four  percent (64%)  of patients  (n=121) in  the trial had cardiovascular
dysfunction  due  to  sepsis  and  36% (n=69)  did  not  at baseline.  For those
patients  with  cardiovascular  dysfunction,  talactoferrin  showed  a  relative
reduction in 28-day all-cause mortality of 22% (28.6% for the placebo arm versus
22.4% for  the talactoferrin arm).  For patients who did not have cardiovascular
dysfunction,  talactoferrin  showed  a  relative  reduction  in 28-day all-cause
mortality of 88% (22.6% for placebo vs. 2.6% in the talactoferrin arm).
Talactoferrin  showed a  trend toward  a decrease  in 28-day all-cause mortality
across  all  baseline  APACHE  II  score  quartiles.  In patients with APACHE II
scores  of 0-18, talactoferrin  reduced mortality  by 56% (8.7%  for placebo vs.
3.8% for   talactoferrin);   in  patients  with  APACHE  II  scores  of  19-23,
talactoferrin   reduced   mortality  by  44% (13.8%  for  placebo  vs.  7.7% for
talactoferrin);  in patients with APACHE  II scores between 24-27, talactoferrin
reduced  mortality by 50% (33.3% for placebo vs. 16.7% for talactoferrin) and in
patients  with scores greater than 27, the  sickest patient group, mortality was
reduced by 42% (60% for placebo vs. 35% for talactoferrin).

In  addition, talactoferrin reduced mortality in patients with different numbers
and  types of organ dysfunctions  at baseline.  For patients  with three or less
organ  dysfunctions  at  baseline  (89%  of  enrolled  patients),  there  was  a
statistically  significant  53% reduction  in  mortality  from 24.4% for placebo
versus  11.4% for  talactoferrin  (two-tailed  p-value  by Fisher's Exact test =
0.03).

Talactoferrin  was  very  well  tolerated  in  the  study  with  no  significant
differences  in adverse events between the  two treatment arms. Of those adverse
events  considered  to  be  possibly  related  to treatment, the most frequently
reported  category in both treatment groups was gastrointestinal disorders (5.6%
of  patients in the talactoferrin arm and  5.3% in the placebo arm).  There were
no   serious   adverse  events  considered  to  be  related  to  treatment  with
talactoferrin.

The  above analyses were all conducted on a modified intent-to-treat basis (also
referred to as intent-to-treat as treated), meaning that patients were evaluated
based  on the treatment they actually received (talactoferrin or placebo) during
the  first week of treatment.   The median number of  treatment days was 6.0 for
the talactoferrin group and 4.5 days for placebo.

All  patients were  centrally screened  for eligibility  prior to randomization.
 The arms were generally well balanced in terms of baseline characteristics.
The  Phase II  trial was  primarily funded  by a  $3 million grant from the U.S.
National Institutes of Health.

About severe sepsis
Sepsis  is a  condition involving  infection and  generalized inflammation.  The
body's normal response to an infection is to set off a limited chain reaction to
fight  the infection.  In  severe sepsis, this  systemic immune response becomes
overactive  and results in damage to vital body organs, leading to a shutdown of
one or more organs and, in many cases, death.  Each year, approximately 750,000
people  in the U.S.  develop severe sepsis,  and a similar  number of people are
affected  in Europe. Due to the aging of the population, this number is expected
to  grow  over  time.   An  estimated  30-40% of  people  with severe sepsis are
expected  to die annually from this condition  in the U.S., and the U.S. Centers
for  Disease Control and Prevention indicates that  sepsis is one of the top ten
leading  causes of death in the U.S.  Patients suffering from severe sepsis must
be hospitalized, often in an intensive care unit, and the medical costs to treat
sepsis were estimated in 2001 to be over $16 billion in the U.S. alone, a number
that is believed to have increased significantly over time.

About talactoferrin
Talactoferrin   is   an   oral   biologic   therapy  with  immunomodulatory  and
antibacterial properties, which is being studied for the treatment of cancer and
severe   sepsis.   Talactoferrin   has   demonstrated  activity  in  randomized,
double-blind,  placebo-controlled Phase II studies in non-small cell lung cancer
(NSCLC),  as well as in severe sepsis. As a result of the promising results from
Phase  II studies, two Phase  III studies with talactoferrin  in NSCLC have been
initiated.   NSCLC is one of  the most common types  of cancer worldwide and the
most   frequent  cause  of  cancer  death.     Agennix  also  plans  to  develop
talactoferrin  further for  the treatment  of severe  sepsis.  Talactoferrin has
been shown to be very well tolerated in these patient populations.

About Agennix
Agennix AG is a publicly traded biopharmaceutical company that is focused on the
development  of novel  therapies to  improve the  length and  quality of life of
seriously  ill patients in areas of major unmet medical need. The Company's most
advanced  program  is  talactoferrin,  an  oral  therapy  that  has demonstrated
activity  in randomized,  double-blind, placebo-controlled  Phase II  studies in
non-small  cell  lung  cancer,  as  well  as  in severe sepsis. Talactoferrin is
currently  in  Phase  III  clinical  trials  in  non-small cell lung cancer, and
Agennix  plans  to  develop  this  program  further  for the treatment of severe
sepsis. Other clinical development programs include RGB-286638, a multi-targeted
kinase   inhibitor   in   Phase  1 testing;  the  oral  platinum-based  compound
satraplatin;  and a topical gel form  of talactoferrin for diabetic foot ulcers.
Agennix's registered seat is in Heidelberg, Germany. The Company has three sites
of  operation: Martinsried/Munich,  Germany; Princeton,  New Jersey and Houston,
Texas.  For  additional  information,  please  visit  the  Agennix  Web  site at
www.agennix.com.

This  press  release  contains  forward-looking  statements,  which  express the
current  beliefs  and  expectations  of  the  management  of  Agennix  AG.  Such
statements  are  based  on  current  expectations  and  are subject to risks and
uncertainties,  many of  which are  beyond our  control, that could cause future
results,  performance or achievements to  differ significantly from the results,
performance  or  achievements  expressed  or  implied  by  such  forward-looking
statements.  There can be no guarantee  that the Company will move talactoferrin
forward  in development for severe sepsis in a timely manner, if at all, or that
talactoferrin  will  ultimately  be  approved  for  sale  in any country. Actual
results could differ materially depending on a number of factors, and we caution
investors  not  to  place  undue  reliance  on  the  forward-looking  statements
contained in this press release. Forward-looking statements speak only as of the
date on which they are made and Agennix undertakes no obligation to update these
forward-looking  statements, even  if new  information becomes  available in the
future.

For further information, please contact:
Agennix AG
Investor Relations & Corporate Communications
Phone: +49 (0)89 8565 2693
ir@agennix.com 

In the U.S.:
Laurie Doyle
Director, Investor Relations & Corporate Communications
Phone: +1 609 524 5884
laurie.doyle@agennix.com 
           Additional media contacts for Europe:
MC Services AG
Phone: +49 (0) 89 210 228 0
Raimund Gabriel
raimund.gabriel@mc-services.eu 

Hilda Juhasz
hilda.juhasz@mc-services.eu 

Additional investor contact for Europe:
Trout International LLC
Lauren (Rigg) Williams, Vice President
Phone: +44 207 936 9325
lwilliams@troutgroup.com 



[HUG#1416364]



 --- End of Message --- 

Agennix AG
Im Neuenheimer Feld 515 Heidelberg Germany

ISIN: DE000A1A6XX4;
Listed: Prime Standard in Frankfurter Wertpapierbörse,
Regulierter Markt in Frankfurter Wertpapierbörse;